Basically, even if there was a prolonged progression-free survival, OS was not statistically different in the two arms.
BUT a strong survival advantage was seen in patients with liver metastasis!
ESMO 2024: Cabozantinib plus Atezoliz... - Advanced Prostate...
ESMO 2024: Cabozantinib plus Atezolizumab versus 2nd novel hormonal therapy inmetastatic CRPC, overall survival results of CONTACT-02 Study
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Apalutamide instead of triple therapy for mHSPC
The triple therapy consists of ADT+Abiraterone+Docetaxel and is often used for patients who present...
ESMO 2024: Phase 3 evaluation of transdermal estradiol vs LHRH agonists for androgen suppression
This is very interesting for us all, even if these results are for non metastatic patients!...
PATCH Study Results
Unless I missed it, I haven't seen a post about the anticipated-this-fall results of the PATCH...
Metformin: Preliminary Results of Trial in Advanced Prostate Cancer (MANSMED)
Not sure if this was posted here yet:
In a mini-oral presentation at this year’s European Society...
Proton pump inhibitor (PPI) use may attenuate the effect of abiraterone acetate plus prednisone (AAP) in metastatic prostate cancer
Proton pump inhibitors (PPIs) are a class of medications that reduce stomach acid production. They...
Related Posts
- we will soon know more about Nubeqa
- Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
Metformin may delay PCa progression.
Tolerability and treatment response to darolutamide in patients with nmCRPC in the phase III ARAMIS trial
Study shows correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients
